Leerink Partnrs Analysts Boost Earnings Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for Intra-Cellular Therapies in a note issued to investors on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of $1.50 for the year, up from their previous forecast of $1.35. The consensus estimate for Intra-Cellular Therapies' current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for Intra-Cellular Therapies' FY2026 earnings at $3.15 EPS and FY2028 earnings at $6.80 EPS.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15. The business had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business's quarterly revenue was up 52.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.46) earnings per share.

ITCI has been the subject of a number of other research reports. The Goldman Sachs Group raised their target price on Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a "neutral" rating in a report on Wednesday, April 17th. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price target on shares of Intra-Cellular Therapies in a report on Tuesday. Bank of America lifted their target price on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a "buy" rating in a research note on Wednesday, April 17th. Robert W. Baird raised their target price on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 17th. Finally, Canaccord Genuity Group upped their price target on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a "buy" rating in a research report on Tuesday, April 23rd. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Intra-Cellular Therapies has a consensus rating of "Moderate Buy" and an average price target of $90.17.

Intra-Cellular Therapies Trading Down 2.1 %

Shares of ITCI traded down $1.44 during mid-day trading on Thursday, hitting $65.56. The company's stock had a trading volume of 718,947 shares, compared to its average volume of 932,051. Intra-Cellular Therapies has a 1-year low of $45.50 and a 1-year high of $84.89. The firm has a market capitalization of $6.35 billion, a P/E ratio of -45.89 and a beta of 1.01. The firm has a 50-day simple moving average of $69.03 and a 200 day simple moving average of $65.86.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Raymond James & Associates grew its holdings in Intra-Cellular Therapies by 4.0% during the 3rd quarter. Raymond James & Associates now owns 149,445 shares of the biopharmaceutical company's stock worth $7,785,000 after acquiring an additional 5,716 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Intra-Cellular Therapies by 1.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 404,329 shares of the biopharmaceutical company's stock worth $21,061,000 after buying an additional 6,182 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Intra-Cellular Therapies by 23.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,764 shares of the biopharmaceutical company's stock worth $717,000 after buying an additional 2,651 shares in the last quarter. Strs Ohio increased its stake in Intra-Cellular Therapies by 3.3% in the 3rd quarter. Strs Ohio now owns 27,900 shares of the biopharmaceutical company's stock worth $1,453,000 after purchasing an additional 900 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Intra-Cellular Therapies by 5.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 45,483 shares of the biopharmaceutical company's stock valued at $2,369,000 after purchasing an additional 2,434 shares during the period. Institutional investors and hedge funds own 92.33% of the company's stock.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, EVP Michael Halstead sold 7,907 shares of the company's stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $69.53, for a total value of $549,773.71. Following the completion of the sale, the executive vice president now owns 29,700 shares of the company's stock, valued at $2,065,041. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, EVP Michael Halstead sold 7,907 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $69.53, for a total transaction of $549,773.71. Following the transaction, the executive vice president now directly owns 29,700 shares of the company's stock, valued at $2,065,041. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Sharon Mates sold 20,565 shares of the firm's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the sale, the chief executive officer now directly owns 1,050,309 shares of the company's stock, valued at $68,490,649.89. The disclosure for this sale can be found here. Insiders have sold 168,487 shares of company stock valued at $11,364,950 over the last three months. 3.40% of the stock is owned by company insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.